Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11560-021-00485-3 http://scihub22266oqcxt.onion/10.1007/s11560-021-00485-3 33532003!7842177!33532003     free     free     free       Nephrologe 2021 ; 16 (3): 129-137 Nephropedia Template TP {{tp|p=33532003|t=2021. COVID-19 und Nierentransplantation |pdf=|usr=}}{{33532003}} gab.com Text COVID-19 und Nierentransplantation JO: Nephrologe http://www.kidney.de/pget.php?&tw=1&pmid=33532003 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic poses a particular risk for kidney transplant recipients. This is due to a high prevalence of comorbidities as well as therapeutic immunosuppression, which plays a complex role in view of the severe hyperinflammation contributing to morbidity and mortality. Many published case series including kidney transplant recipients reported a high proportion of hospitalized cases and mortality rates of 13-23%. The clinical symptoms and established risk factors for severe disease seem to be similar to those of the general population. The management of immunosuppressive treatment is a delicate question in the treatment of kidney transplant recipients with COVID-19. According to the current recommendations, a stepwise reduction should be carried out depending on the clinical course of the disease. Ongoing efforts to find an effective treatment for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) focus on repurposing known antiviral and anti-inflammatory substances. To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing. Twit Text FOAVip COVID-19 und Nierentransplantation ????Nephrologe http://www.kidney.de/pget.php?&tw=1&pmid=33532003 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33532003 #FOAvip English Wikipedia <ref>{{Cite pmid|33532003}}</ref> COVID-19 und Nierentransplantation #MMPMID33532003 Regele F; Oberbauer R Nephrologe 2021[]; 16 (3): 129-137 PMID33532003show ga The coronavirus disease 2019 (COVID-19) pandemic poses a particular risk for kidney transplant recipients. This is due to a high prevalence of comorbidities as well as therapeutic immunosuppression, which plays a complex role in view of the severe hyperinflammation contributing to morbidity and mortality. Many published case series including kidney transplant recipients reported a high proportion of hospitalized cases and mortality rates of 13-23%. The clinical symptoms and established risk factors for severe disease seem to be similar to those of the general population. The management of immunosuppressive treatment is a delicate question in the treatment of kidney transplant recipients with COVID-19. According to the current recommendations, a stepwise reduction should be carried out depending on the clinical course of the disease. Ongoing efforts to find an effective treatment for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) focus on repurposing known antiviral and anti-inflammatory substances. To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing. äCOVID-19 und Nierentransplantation (epmc).pdf DeepDyve Pubget Overpricing